TP53 and anaplastic large cell lymphoma: We show in vivo that brigatinib is effective in inducing the remission of PDX models of crizotinib‐resistant (ALK C1156Y, TP53 loss) ALCL and furthermore that it is superior to crizotinib as a second‐line approach to the treatment of a standard chemotherapy relapsed/refractory ALCL PDX pointing to brigatinib as a future therapeutic option.